Print

Annual Report 2007 Active Biotech AB (publ)

2008-05-07

As from now, the Annual Report will only be digitally distributed.
Lund, May 7, 2008
Active Biotech AB (publ)
Sven Andréasson
President & CEO
For further information, please contact:
Cecilia Hofvander
Manager Corporate Communication
Tel +46 (0)46 19 11 22
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer-targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA.
Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel +46 (0)46-19 20 00
Fax +46 (0)46-19 20 50

pdf



Back